Results of the voluntary partial tender offers
24 juil. 2019 06h30 HE
|
Biofrontera AG
Leverkusen, Germany, July 24, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...
Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority
11 juil. 2019 05h23 HE
|
Biofrontera AG
Leverkusen, Germany, July 11, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Biofrontera Reports First Quarter 2019 Financial Results
29 mai 2019 03h11 HE
|
Biofrontera AG
Leverkusen, Germany, May 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
16 mai 2019 04h30 HE
|
Biofrontera AG
Leverkusen, Germany, May 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera Reports Full Year 2018 Financial Results
29 avr. 2019 02h00 HE
|
Biofrontera AG
Leverkusen, Germany, April 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019
26 avr. 2019 09h20 HE
|
Biofrontera AG
Leverkusen, Germany, April 26, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced in...
Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
16 avr. 2019 07h30 HE
|
Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
15 avr. 2019 06h15 HE
|
Biofrontera AG
Leverkusen, Germany, April 15, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH
02 avr. 2019 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, April 02, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...
Changes in the composition of the Supervisory Board
27 mars 2019 09h05 HE
|
Biofrontera AG
Leverkusen, Germany, March 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...